The monoamine oxidase A (MAOA)—metabolizing catecholamines such as norepinephrine and serotonin and being a target of potent antidepressants such as tranylcypromine—has been suggested as a key player in the pathogenesis of anxiety and mood disorders (for review see Ziegler and Domschke 2018). Here, MAOA is linked to mood disorder.